These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33087329)

  • 1. Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Hong B; Chapa V; Saini U; Modgil P; Cohn DE; He G; Siddik ZH; Sood AK; Yan Y; Selvendiran K; Pei G; Zhao Z; Yoo JY; Kaur B
    Clin Cancer Res; 2021 Jan; 27(2):542-553. PubMed ID: 33087329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Grabosch S; Bulatovic M; Zeng F; Ma T; Zhang L; Ross M; Brozick J; Fang Y; Tseng G; Kim E; Gambotto A; Elishaev E; P Edwards R; Vlad AM
    Oncogene; 2019 Mar; 38(13):2380-2393. PubMed ID: 30518877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer.
    Fujiwara S; Nawa A; Luo C; Kamakura M; Goshima F; Kondo C; Kiyono T; Kikkawa F; Nishiyama Y
    Cancer Gene Ther; 2011 Feb; 18(2):77-86. PubMed ID: 20885447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
    Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
    Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
    Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
    Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis.
    Sasso E; Froechlich G; Cotugno G; D'Alise AM; Gentile C; Bignone V; De Lucia M; Petrovic B; Campadelli-Fiume G; Scarselli E; Nicosia A; Zambrano N
    Sci Rep; 2020 Mar; 10(1):4307. PubMed ID: 32152425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.
    Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.
    Farrell CJ; Zaupa C; Barnard Z; Maley J; Martuza RL; Rabkin SD; Curry WT
    Clin Cancer Res; 2008 Dec; 14(23):7711-6. PubMed ID: 19047097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
    Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
    Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
    Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
    PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
    Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.
    de Queiroz NMGP; Xia T; Konno H; Barber GN
    Mol Cancer Res; 2019 Apr; 17(4):974-986. PubMed ID: 30587523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer.
    Huang S; Hu H; Tang G; Liu K; Luo Z; Zeng W
    Arch Virol; 2023 Mar; 168(4):128. PubMed ID: 37002434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.